Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (501)	3/30/1999 1:18:00 PM
From: mesaone	Read Replies (1) \| Respond to of 10293

We shall see. Biotime filed their NDA for Hextend exactly one year ago, 3/31/98.. everyone is anticipating approval this week, or next week. It will be interesting to see what ABT has in store for marketing and selling Hextend, I believe ABT has a conference call on 4/8.. maybe they might tighten their estimates for revenues from Hextend (the last conference call they did say it could be up to $400 million... but that was the outside number).. Bill, I dont know why you continue to think it will trade for $5.00, but one thing is for sure.. there are no shares available to short.. the UPC code has been up on everyones screen for weeks now, and the shorts did not cover (over 2 million shorted)...this stock is primed for an explosion imho.. You did cover your short this summer, did you not? Too bad that Asensio hasn't .

To: Bill Wexler who wrote (501)	3/30/1999 2:39:00 PM
From: mesaone	Read Replies (1) \| Respond to of 10293

Abbott reported today that they signed a deal with Consorta, Inc. This is the sole source contract for intravenous solutions and related products valued at nearly $500 million. biz.yahoo.com it is interesting to note that Hextend, BioTime's first product, a blood plasma expander, will be manufactured and marketed by Abbott.. and today, Abbott has just guaranteed a captive buying audience. I think that perhaps the shorts here should think about revising their estimate on BTIM .. this is great news for BTIM imho.. especially with approval coming very soon.